# S-1 Versus 5-FU Bolus in Metastatic Pancreatic Cancer Patients Previously Treated With Gemcitabine-Based Regimen

> **NCT00602745** · PHASE3 · TERMINATED · sponsor: **Sanofi** · enrollment: 61 (actual)

## Conditions studied

- Pancreatic Neoplasm
- Neoplasm Metastasis

## Interventions

- **DRUG:** S-1
- **DRUG:** 5-Fluorouracil

## Key facts

- **NCT ID:** NCT00602745
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-02
- **Primary completion:** 2010-03
- **Final completion:** 2010-03
- **Target enrollment:** 61 (ACTUAL)
- **Why stopped:** Following the termination of development and commercialization agreement for S-1 with Taiho Pharmaceutical
- **Last updated:** 2016-05-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00602745

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00602745, "S-1 Versus 5-FU Bolus in Metastatic Pancreatic Cancer Patients Previously Treated With Gemcitabine-Based Regimen". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00602745. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*